Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2888)	12/28/2010 11:08:36 AM
From: Jibacoa	Respond to of 3722

ATHX was up 26.10% earlier, but is up only 9.24% at present with volume of > 621Ks already about 9.8x its ADV.<g> bigcharts.marketwatch.com There are no recent news that I am aware. The previous spike was when PFE announced that it was making an investment in ATHX and paying it to develop a treatment for inflammatory bowel disease. That investment was of $6M upfront and $105M in potential milestones.<g> ATHX is also developing therapies for heart disease, stroke and bone marrow transplant. <g> There seems to be renewed interest on stem cells, with GERN also moving up yesterday, although not so today.<g> The ACTAY on ATHX is $6.98 The stock hasn't completely closed its Dec2009 UG and has a good amount of resistance from the $3 to $4 level. bigcharts.marketwatch.com But it seems worth to keep an eye on it.<g> Bernard